Abstract
I wish to applaud the efforts of Moffatt et al1 to dispel the idea promulgated by its manufacturer that administering deamino-8-D-arginine vasopressin (DDAVP) is the most effective, or is even a particularly effective, treatment for nocturnal enuresis. However, I was disappointed in the accompanying editorial by Rappaport2 in two regards. He mentions, without questioning, the suggestion "that at least a component of the etiology of enuresis is secondary to a deficiency of a nocturnal surge of antidiuretic hormone (ADH)."
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
